Evidence map›Paper›PMID 40465679›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Alzheimer's disease plasma biomarkers in the Midwestern Amish.

Ping Wang, Yeunjoo E Song, Audrey Lynn, Kristy Miskimen, Alex Gulyayev, Michael B Prough, Daniel A Dorfsman, Renee A Laux, Sarada L Fuzzell, Sherri D Hochstetler and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Alzheimer's disease plasma biomarkers in the Midwestern Amish.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ping WangDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0009-0005-8478-466X
Yeunjoo E SongDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Audrey LynnDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Kristy MiskimenDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Alex GulyayevJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Michael B ProughJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Daniel A DorfsmanJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Renee A LauxDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Sarada L FuzzellDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Sherri D HochstetlerDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Andrew F ZamanJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Larry D AdamsJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Laura J CaywoodJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Jason E ClouseJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Sharlene D HeringtonJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Patrice WhiteheadJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Yining LiuDepartment of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Noel MooreDepartment of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Paula OgrockiDepartment of Neurology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Alan J LernerDepartment of Neurology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Anthony J GriswoldJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Jeffery M VanceJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Michael L CuccaroJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
William K ScottJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Margaret A Pericak-VanceJohn P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Jonathan L HainesDepartment of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

Funding

NIA NIH HHS AG019085NIA NIH HHS AG019726NIA NIH HHS AG058066
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) plasma biomarkers are non-invasive measures of the key amyloid beta (Aβ) and tau pathologies. Validation and generalization studies are needed to fully understand their potential for AD prediction and diagnosis in the elderly population.

methodsIn 1067 Amish individuals aged ≥ 65, we measured plasma Aβ and tau to assess their relationships with AD-related outcomes.

resultsAmong Amish individuals with AD, plasma phosphorylated tau protein at epitope 181 (p-tau181) was significantly higher (p = 0.04), and plasma Aβ42/p-tau181 ratio was significantly lower (p = 0.01) than cognitively normal individuals. The association of AD with elevated p-tau181 was driven by apolipoprotein E (APOE) ε4 carriers (odds ratio = 6.02, p < 0.001). Cluster analysis identified two subgroups defined by differing Aβ and tau levels, with the high-risk cluster having more APOE ε4 carriers (p < 0.001). DISCUSSION: Plasma biomarkers, particularly p-tau181, Aβ42/Aβ40, and Aβ42/p-tau181 ratio, are promising surrogate biomarkers for AD-related pathology and clinical outcomes in the Amish.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPeptide Fragmentstau ProteinsAgedAged, 80 and overApolipoprotein E4BiomarkersFemaleHumansMaleMidwestern United StatesPhosphorylationAmyloid beta-Peptidesamyloid beta-protein (1-42)Apolipoprotein E4BiomarkersMAPT protein, humanPeptide Fragmentstau ProteinsAlzheimer's diseasecluster analysiscognitive functionfounder populationplasma biomarkers

Identifiers

PMID40465679
PMCPMC12136092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.